Showing results (281-290 of 378) with videos related to

Sort By:
Pageof 38
Plos One|June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial dataCaroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
American Journal of Human Genetics|December 11, 2002
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 geneStephen M Edwards, Zsofia Kote-Jarai, Julia Meitz, et al.
Neuro-Oncology Advances|June 30, 2022
Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysisMueez Waqar, Federico Roncaroli, Eric J Lehrer, et al.
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
Clinical and Translational Radiation Oncology|February 20, 2020
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trialJulia Murray, Sarah Gulliford, Clare Griffin, et al.
Research Involvement and Engagement|July 2, 2025
Patient and public involvement in the SPRUCE methodology study investigating electronic patient reported outcomes in oncology clinical trialsMorgaine Stiles, Monisha Dewan, Georgina Manning, et al.
British Journal of Cancer|October 21, 2021
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penisSteve Nicholson, Holly Tovey, Tony Elliott, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2019
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancerJulia Murray, Clare Griffin, Sarah Gulliford, et al.
European Urology|October 4, 2018
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)John D Kelly, Wei Shen Tan, Nuria Porta, et al.
European Urology Focus|July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyDavid Lorente, Praful Ravi, Niven Mehra, et al.
Pageof 38